Israel Judea and Samaria Pompeo Trump

CJA STATEMENT: President Trump: A Trailblazer for Truth and Courage, a Partner in Jewish Destiny

November 18, 2019 — Conference of Jewish Affairs spokesman Rabbi Aryeh Spero made the following statement today regarding the Administration’s announcement that the United States will no longer consider Israeli settlements in Judea and Samaria, the Golan Heights and East Jerusalem as “inconsistent with international law”.

“Conference of Jewish Affairs endorses President Trump’s and Secretary Pompeo’s breakthrough thinking and willingness to seek out and abide by historic and legal truths.

“President Trump and Secretary Pompeo are to be commended and admired for recognizing Israel’s historic and legal right to build housing on the Jewish land of Judea and Samaria and for boldly recognizing the right of individual Jews and the Jewish nation of Israel to implant communities and Jewish social life on the ancestral and holy ground which constitutes Eretz Israel.

“President Trump and Secretary Pompeo are trailblazers and the world is fortunate for their courage, vision, and consummate abilities.”

Rabbi Spero concluded, “Israel and the Jewish People have never had a greater friend than President Donald J. Trump.”

Israel Israeli Achievements Israeli Medical Discoveries

Israeli Researcher Discovers Protein that May Eradicate Cancer

by Sophie Imas , originally published on

“Killing these cancer stem cells is the holy grail of cancer treatments and therefore holds promise for complete eradication of cancer,” says Dr. Sarit Larisch of the University of Haifa.

These are not words pronounced lightly; instead, they follow more than a decade of research that could give hope to cancer patients worldwide. Along with her colleagues, Larisch has established the basis for developing a new, more effective treatment for cancer using a protein called ARTS.

ARTS is a protein, which along with a number of other proteins and enzymes, regulates what is known as apoptosis. Apoptosis is the process of programmed cell death which occurs when a cell is damaged, mutated or no longer functional. ARTS acts as a trigger for cell death, its presence allowing for enzymes called caspases to destroy the non-functional cell.

But this process is missing in cancer cells.

Destroying cancer cells using the natural process of self-destruction

Larisch’s research shows that unlike normal cells, cancer cells have an absence of the ARTS protein. “Without the ARTS protein, cells can’t be triggered to self-destruct. As a result cancer cells can survive and develop into a tumor,” she tells NoCamels.

“We have found that ARTS is lost in many types of cancers. Therefore, determining levels of ARTS in blood could provide a marker to alert to the possibility of developing certain types of cancers.” Consequently, Dr. Larisch believes that small molecules that mimic ARTS could restore the ability of cancer cells to be killed selectively using the natural process of apoptosis.

“ARTS-based cancer drugs could potentially change the treatment method of cancer worldwide,” Larisch tells NoCamels. “We have found that ARTS is particularly important for the death of defective stem cells. We therefore believe that ARTS-based drugs will specifically eliminate cancer stem cells (the cells that drive the growth of a tumor and are often resistant to chemotherapy or radiotherapy).

The therapy would also minimize common side-effects of conventional cancer treatment. “All currently available cancer drugs have unwanted side effects because they harm normal cells as well. In contrast, ARTS-based cancer drugs should only kill cancer cells because they act by specifically correcting the defect in their cell suicide program, caused by the loss of ARTS,” says Larisch.

13 years in the making

Dr. Sarit Larisch discovered the protein during her post-doctoral studies at the NCI/NIH , Bethesda, MD. This discovery was first published in the journal “Nature Cell Biology” in the year 2000. She has been working on this project ever since and has revealed how ARTS is essential for cell death on a molecular level. Cancer research was Larisch’s initial interest, which she returned to after the discovery of ARTS.

“After completing my PhD in Tumor Immunology, I became very interested in apoptosis. The decisions a cell makes which determine whether it will live or die fascinated me.” It was not until further in her career, when Larisch discovered the connection between the ARTS protein and cancer, that she began focusing on using the information gathered about this protein for the development of novel ways for cancer diagnosis and treatment.

Despite the success of her work, Larisch says that finding support and funding was not always easy. “I consider myself very lucky with the research support that we’ve gotten. Unfortunately, developing cancer drugs is very costly and goes beyond typical academic budgets. Right now, we’re ready to start developing ARTS-based cancer drugs. But we need more funding, to move full speed ahead.”

Her research received funding from the Israeli Science Foundation, the United States – Israel Binational Research Foundation (BIRD), as well as some private donors.

Larisch completed her education at the Hadassah Medical School of the Hebrew University of Jerusalem. She moved on to obtain her post-doctorate degree at the National Cancer Institute/NIH in the United States. Upon discovering the ARTS protein, she returned to Israel and founded her own research laboratory. She is currently the head of the Biology and Medical Sciences department at the University of Haifa. Larisch has had a Visiting Professor appointment at the Rockefeller University in New York for the past 12 years, where she works in close collaboration with Professor Hermann Steller and members of his lab.

Currently, she and her colleagues are in contact with several investors and pharmaceutical companies to obtain funding for ARTS-based cures. Larisch hopes to start developing ARTS-based cancer drugs as soon as possible and establish the ARTS protein as a biomarker of susceptibility to cancer.

by Sophie Imas , originally published on  (Our thanks to United For Israel for forwarding this.)

Israel Israeli Achievements Medical Discoveries

Israeli Invention: A ‘watch’ that stops unnecessary heart attack deaths

GE is banking on Oxitone wrist monitor to provide a heads-up for someone to get medical assistance before it’s too late.

By Karin Kloosterman. Israel21c.

A prototype of the Oxitone device, heading to market in about 18 months.

About half of all people at risk of death from heart attacks could gain the chance to live, once Israeli entrepreneur Leon Eisen’s new Oxitone device goes to market in about 18 months.

Using two optical sensors, and another special high-tech tool, he’s developed the world’s first “watch” that can just about tell when your time may be up.

It’s no joke: Oxitone was developed to cheat fate.

Eisen tells ISRAEL21c that about half of the people who die from cardiac or pulmonary arrest would be alive if someone had been there to get them to the hospital in time. Oxitone is made to be worn on the wrist to provide a heads-up for someone to get medical assistance on their own, before it’s too late.

With all the technology out there — personal monitoring devices, crocodile clips for your finger, even those panic buttons — nothing helps if the user is not able to mobilize these devices in time. And many patients may not be able to read the signs that cardiac arrest is imminent.

That’s why Eisen developed a wearable watch-like mobile device –– synched with Bluetooth, Android or iPhone devices –– that takes minute-by-minute readings of heart rate and oxygen levels in the blood.

So potentially “disruptive” is this advance that Oxitone recently was chosen from 400 applicants to be among 13 companies – and the only Israeli one — in GE Healthcare’s Start-Up Health Academy Entrepreneurship Program. The three-year program provides healthcare entrepreneurs the tools to propel their product into the healthcare market.

Pain-free, always on duty

“Oxitone takes the pinch out; it’s worn on the wrist instead of the fingertip to provide continuous, wireless non-stop monitoring while you are walking, eating, sleeping or doing sports,” Eisen says.

Blood-oxygen levels are a critical parameter in monitoring COPD (chronic obstructive pulmonary disease), which can prevent patients from getting enough air into their lungs.

COPD also accompanies chronic bronchitis, asthma and emphysema, leading to shortness of breath. It is estimated that COPD is the third-highest cause of death in the United States.

Oxitone non-invasively determines if a cardiac event is imminent by following blood-oxygen levels. It may also help people who suffer from sleep apnea, giving peace of mind to the wearer and their loved ones.

It looks like a watch, but it’s a sophisticated blood-oxygen and heart-rate monitor.

When heart rates change and oxygen levels drop, Oxitone sends alerts to pre-determined locations. It can also be used for long-term care, as physicians can access ongoing records to see how a patient is doing over time.

“My product facilitates an early clinical response for cardiac or pulmonary attack,” Eisen explains. “Because it is continuously monitoring, we can provide an emergency alert. With our device, people will feel better because they understand they are protected. This is the breakthrough.”

A telltale heart

Eisen is looking for a $3 million investment and looks forward to starting clinical trials on the device in Israel and the UK. Early R&D trials have already been done, he says. There is also a working prototype in hand, but just how the final Oxitone will look is yet to be determined.

Eisen was trained originally as a physicist. The 46-year-old moved to Israel from Moscow in 1999 and obtained a doctorate from Israel’s famed Weizmann Institute of Science. He then did a post-doc at Bar-Ilan University, where he learned about optical lasers. This work of several years enchanted him, and made him curious about applied sciences.

He started working as a freelancer, building various projects and sensors for high-tech companies.

In 2010, Eisen joined Israel’s startup nation culture by founding Oxitone, the name of the company as well as the device. The company is based in Ashkelon, inside the ATI incubator.

The “watch” will cost an estimated $200, plus a monthly service fee depending on use.


Israel Israeli Achievements

Billionaire Buffett: ‘There is No Other Place in the World’ Like Israel

by Zach Pontz, Algemeiner Journal.

Warren Buffett meets with U.S. President Barack Obama at the White House. Photo: Wikipedia..

Super investor Warren Buffett,recently named to The Algemeiner’s Jewish 1oo list for his strong support of Israeli innovation, completed his acquisition of Israeli company Iscar Wednesday. Buffett’s Berkshire Hathaway Inc., antied up the $2 billion it needed to acquire a full stake after investing $4 billion for 80% of the company in 2006.

“I spoke with Eitan (Wertheimer, Chairman of Iscar) in January in Washington, and we decided that this was the time for us and the family to make the deal. I am very pleased,” Buffett said, when asked why he waited seven years to acquire full ownership of the company.

In an interview with Israel Hayom after the transaction, Buffett heaped praise on Israel.

“Israel is a great place to invest because of its people. There is no other place in the world where you find people with these qualities, as well as with the motivation and the ability to focus that you see at Iscar,” he told the Israeli newspaper.

With Buffett being the investor that he is, there was the inevitable financial advice query, to which Buffett responded: “I haven’t been to Israel recently so its hard for me to give advice, but I form my impressions from Iscar, and the company makes me believe that Israel has a bright future. Iscar will never stop, even if there is a slowdown in world markets. Iscar never stops innovating with new products and never stops satisfying its customers. With the excellent management at Iscar, I just sit in the back seat and let the car drive itself. I don’t have to do anything but rely on the management.”

Buffett, one of the richest men alive, does, however, have advice for Israel as a whole. “Israel should continue to do what it’s doing. You are a nation of entrepreneurs with amazing abilities. Israel must continue to provide them with the best and most comfortable work climate. That is the government’s responsibility: to create a comfortable climate for entrepreneurs.”

Foreign Policy Iran Israel Jerusalem Jewish Affairs Journal Middle East Nuclear threat Obama

OPINION — Charles Krauthammer: The Abandonment

By Charles Krauthammer, Washington Post, September 13, 2012

There are two positions one can take regarding the Iranian nuclear program: (a) it doesn’t matter, we can deter them; or (b) it does matter, we must stop them.
In my view, the first position – that we can contain Iran as we did the Soviet Union – is totally wrong, a product of wishful thinking and misread history. But at least it’s internally coherent.

What is incoherent is President Obama’s position. He declares the Iranian program intolerable – “I do not have a policy of containment; I have a policy to prevent Iran from obtaining a nuclear weapon” – yet stands by as Iran rapidly approaches nuclearization.

Read more: